<code id='A41CC6210D'></code><style id='A41CC6210D'></style>
    • <acronym id='A41CC6210D'></acronym>
      <center id='A41CC6210D'><center id='A41CC6210D'><tfoot id='A41CC6210D'></tfoot></center><abbr id='A41CC6210D'><dir id='A41CC6210D'><tfoot id='A41CC6210D'></tfoot><noframes id='A41CC6210D'>

    • <optgroup id='A41CC6210D'><strike id='A41CC6210D'><sup id='A41CC6210D'></sup></strike><code id='A41CC6210D'></code></optgroup>
        1. <b id='A41CC6210D'><label id='A41CC6210D'><select id='A41CC6210D'><dt id='A41CC6210D'><span id='A41CC6210D'></span></dt></select></label></b><u id='A41CC6210D'></u>
          <i id='A41CC6210D'><strike id='A41CC6210D'><tt id='A41CC6210D'><pre id='A41CC6210D'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:comprehensive    Page View:86
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In